13,088 Shares in Lifecore Biomedical, Inc. $LFCR Acquired by GWN Securities Inc.

GWN Securities Inc. bought a new position in shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 13,088 shares of the company’s stock, valued at approximately $106,000.

Several other large investors have also added to or reduced their stakes in the business. Goldman Sachs Group Inc. grew its stake in Lifecore Biomedical by 16.8% during the first quarter. Goldman Sachs Group Inc. now owns 87,998 shares of the company’s stock worth $620,000 after purchasing an additional 12,647 shares during the period. Bank of New York Mellon Corp grew its stake in Lifecore Biomedical by 3.8% during the first quarter. Bank of New York Mellon Corp now owns 83,663 shares of the company’s stock worth $589,000 after purchasing an additional 3,091 shares during the period. Charles Schwab Investment Management Inc. grew its stake in Lifecore Biomedical by 6.8% during the first quarter. Charles Schwab Investment Management Inc. now owns 79,495 shares of the company’s stock worth $560,000 after purchasing an additional 5,068 shares during the period. Boston Partners acquired a new stake in Lifecore Biomedical during the first quarter worth approximately $241,000. Finally, Nuveen LLC acquired a new stake in Lifecore Biomedical in the first quarter valued at approximately $203,000. Institutional investors and hedge funds own 83.36% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Weiss Ratings reissued a “sell (d)” rating on shares of Lifecore Biomedical in a research note on Wednesday, October 8th. KeyCorp assumed coverage on Lifecore Biomedical in a research note on Wednesday, September 3rd. They issued a “sector weight” rating for the company. Finally, Wall Street Zen raised Lifecore Biomedical from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $8.00.

Lifecore Biomedical Stock Up 0.6%

Shares of NASDAQ:LFCR opened at $7.10 on Friday. The stock has a market cap of $266.04 million, a price-to-earnings ratio of -5.42 and a beta of 0.62. The company has a quick ratio of 1.77, a current ratio of 2.84 and a debt-to-equity ratio of 113.76. Lifecore Biomedical, Inc. has a 12-month low of $4.76 and a 12-month high of $8.85. The business’s 50 day moving average is $7.20 and its 200 day moving average is $7.17.

Lifecore Biomedical (NASDAQ:LFCR) last announced its earnings results on Monday, April 1st. The company reported ($0.22) earnings per share (EPS) for the quarter. The company had revenue of $26.54 million for the quarter. Lifecore Biomedical had a negative net margin of 31.70% and a negative return on equity of 846.51%. Lifecore Biomedical has set its FY 2024 guidance at EPS. On average, sell-side analysts forecast that Lifecore Biomedical, Inc. will post -0.91 earnings per share for the current fiscal year.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.